首页> 外文学位 >Synthesis, Characterization, In Vitro Evaluation, and Preclinical Profiling of beta-Cyclodextrin Polyrotaxane Families for Use As Potential Niemann-Pick Type C Therapeutics.
【24h】

Synthesis, Characterization, In Vitro Evaluation, and Preclinical Profiling of beta-Cyclodextrin Polyrotaxane Families for Use As Potential Niemann-Pick Type C Therapeutics.

机译:β-环糊精聚轮烷家族的合成,表征,体外评估和临床前分析,可用作潜在的尼曼-匹克C型治疗药物。

获取原文
获取原文并翻译 | 示例

摘要

Niemann-Pick Disease Type C (NPC) is a rare, autosomal recessive genetic disorder featuring a loss of proteins responsible for unesterified cholesterol (UC) trafficking through the late endosomes/lysosomes (LE/LY) of every cell of the body. Disruption of this pathway leads to abnormal accumulation and storage of UC and other lipids. A broad range of visceral and neurological symptoms result from this accumulation exhibiting a variable age of onset and a disease progression that is ultimately fatal. The disease has an incidence of approximately 1 in 120,000 live births and has no known effective treatment. beta-Cyclodextrin (beta-CD) are natural small molecules macrocycles composed of glucose units with a hydrophobic inner cavity and hydrophilic outer rims. beta-CD derivatives have recently been shown to be effective therapeutics for NPC in cellular and animal models. In the mouse model of the disease, beta-CD therapy increases overall lifetime by as much as 50% and slows the progression of neurodegeneration. The progress has led to the initiation of a National Institutes of Health phase I clinical trial. A main drawback of beta-CD administration is the poor pharmacokinetic profile characterized by rapid renal clearance of the drug through the urine. Libraries of beta-CD derivative carrying high molecular weight polyrotaxane (PR) systems have been designed to prevent glomerular filtration of the injected beta-CD dose. An initial family of unmodified beta-CD PRs was synthesized, characterized, and their therapeutic efficacy was tested in NPC fibroblasts. This was followed by screening of PRs consisting of mixed beta-CD derivative threading featuring charged sulfobutylether beta-CD. Finally, we sought to define PR structure-property effects on in vivo pharmacokinetics, biodistribution, toxicity, immunogenicity, and protein hard corona composition. This was accomplished using a family of gadolinium carrying PRs composed of triblock Pluronic co-polymers of varying molecular weights and hydrophilic/lipophilic ratios. The effect of varying threaded beta-CD derivative surface chemistry on PR mediated hemolysis and hard protein corona was also studied. Knowing if structure-property relationships exist in the in vivo performances of PR materials will help with building pre-clinical profile, selecting candidate materials for a given application, and understanding therapeutic outcomes.
机译:尼曼-匹克病C型(NPC)是一种罕见的常染色体隐性遗传疾病,其特征是丢失负责通过体内每个细胞的晚期内体/溶酶体(LE / LY)转运未酯化胆固醇(UC)的蛋白质。该途径的破坏导致UC和其他脂质的异常积累和储存。这种积聚导致广泛的内脏和神经系统症状,表现出可变的发病年龄和最终致命的疾病进展。该疾病的发病率约为120,000例活产中的1例,尚无有效的治疗方法。 β-环糊精(β-CD)是天然小分子大环,由具有疏水性内腔和亲水性外缘的葡萄糖单元组成。 β-CD衍生物最近在细胞和动物模型中显示出对NPC有效的治疗方法。在该疾病的小鼠模型中,β-CD治疗可将整体寿命延长多达50%,并减缓神经变性的进程。这一进展导致启动了美国国立卫生研究院第一阶段临床试验。 β-CD给药的主要缺点是药物动力学较差,其特征是药物通过尿液迅速清除肾脏。设计了带有高分子量聚轮烷(PR)系统的β-CD衍生物库,以防止肾小球滤过注射的β-CD剂量。合成了未经修饰的β-CDPRs初始家族,进行了表征,并在NPC成纤维细胞中测试了其治疗功效。随后筛选由混合的带电荷磺基丁基醚β-CD的混合β-CD衍生物组成的PR。最后,我们试图定义PR结构性质对体内药代动力学,生物分布,毒性,免疫原性和蛋白质硬质电晕组成的影响。这是使用带有PR的PR系列完成的,这些PR由分子量和亲水/亲脂比不同的三嵌段Pluronic共聚物组成。还研究了不同螺纹的β-CD衍生物表面化学对PR介导的溶血和硬蛋白电晕的影响。知道PR材料的体内性能中是否存在结构-属性关系将有助于建立临床前概况,选择给定应用的候选材料并了解治疗结果。

著录项

  • 作者

    Collins, Christopher J.;

  • 作者单位

    Purdue University.;

  • 授予单位 Purdue University.;
  • 学科 Chemistry.;Materials science.;Nanoscience.
  • 学位 Ph.D.
  • 年度 2015
  • 页码 286 p.
  • 总页数 286
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号